Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

ClinicalTrials.gov ID: NCT01180634

Public ClinicalTrials.gov record NCT01180634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin™) In Stable Cystic Fibrosis Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Decreased efficacy, intolerance and high treatment burden with currently available therapies indicate a need for additional therapies. MP-376 (Aeroquin™) is a novel formulation of the fluoroquinolone levofloxacin that has been optimized for aerosol delivery. Preclinical and clinical studies conducted to date show that aerosol doses of MP-376 are safe and well tolerated, exert an antimicrobial effect, improve lung function and reduce the need for other anti-pseudomonal antibiotics. High concentrations of levofloxacin in the lung delivered as MP-376 are active against CF pathogens including those with high minimum inhibitory concentration (MIC) levels to aminoglycosides such as tobramycin (TOBI®) and other inhaled antimicrobial agents. Inhaled MP-376 can be delivered rapidly and efficiently using a customized PARI investigational configuration of the eFlow® nebulizer system.

Study identification

NCT ID
NCT01180634
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
330 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 3, 2010
Primary completion
May 6, 2012
Completion
May 6, 2012
Last update posted
Dec 17, 2024

2010 – 2012

United States locations

U.S. sites
95
U.S. states
41
U.S. cities
85
Facility City State ZIP Site status
Not listed Mobile Alabama 36608
Not listed Anchorage Alaska 99508
Not listed Phoenix Arizona 85016
Not listed Tucson Arizona 85724
Not listed La Jolla California 92037
Not listed Long Beach California 90806
Childrens Hospital Los Angeles California 90027
Not listed Los Angeles California 90033
Not listed Oakland California 94611
Not listed Orange California 92868
Not listed Palo Alto California 94304
Not listed Sacramento California 95817
Not listed San Diego California 92103
Not listed San Francisco California 94115
Not listed San Francisco California 94143
Not listed Aurora Colorado 80045
Not listed Denver Colorado 80206
Not listed Hartford Connecticut 06106
Not listed Wilmington Delaware 19803
Not listed Jacksonville Florida 32207
Not listed Miami Florida 33136
Not listed Orlando Florida 32801
Not listed St. Petersburg Florida 33701
Not listed Tampa Florida 33606
Not listed Atlanta Georgia 30322
Not listed Boise Idaho 83712
Not listed Chicago Illinois 60614
Not listed Chicago Illinois 60637
Not listed Glenview Illinois 60025
Not listed Niles Illinois 60714
Not listed Indianapolis Indiana 46202
Not listed Wichita Kansas 67214
Not listed Lexington Kentucky 40536
Not listed Louisville Kentucky 40202
Not listed New Orleans Louisiana 70011
Not listed Portland Maine 04102
Not listed Boston Massachusetts 02114
Not listed Boston Massachusetts 02115
Not listed Worcester Massachusetts 01655
Not listed Ann Arbor Michigan 48109
Not listed Detroit Michigan 48201
Not listed Grand Rapids Michigan 49503
Not listed Minneapolis Minnesota 55455
Not listed Jackson Mississippi 39216
Not listed Columbia Missouri 65212
Not listed Kansas City Missouri 64108
Not listed St Louis Missouri 63104
Not listed St Louis Missouri 63110
Not listed Omaha Nebraska 68198
Not listed Las Vegas Nevada 89107
Not listed Lebanon New Hampshire 03756
Not listed Manchester New Hampshire 03104
Not listed Livingston New Jersey 07039
Not listed Long Branch New Jersey 07440
Not listed Morristown New Jersey 07962
Not listed Albuquerque New Mexico 87131
Not listed Albany New York 12208
Not listed New York New York 10003
Not listed New York New York 10011
Not listed New York New York 10032
Not listed Syracuse New York 13210
Not listed Valhalla New York 10595
Not listed Chapel Hill North Carolina 27599
Not listed Akron Ohio 44308
Not listed Cincinnati Ohio 45229
Not listed Columbus Ohio 43205
Not listed Dayton Ohio 45404
Not listed Toledo Ohio 43606
Not listed Oklahoma City Oklahoma 73104
Not listed Oklahoma City Oklahoma 73112
Not listed Hershey Pennsylvania 17033
Not listed Philadelphia Pennsylvania 19102
Not listed Philadelphia Pennsylvania 19104
Not listed Pittsburgh Pennsylvania 15224
Not listed Charleston South Carolina 29425
Not listed Columbia South Carolina 29203
Not listed Sioux Falls South Dakota 57117
Not listed Memphis Tennessee 38105
Not listed Nashville Tennessee 37232
Not listed Austin Texas 78723
Not listed Dallas Texas 75390
Not listed Fort Worth Texas 76104
Not listed Houston Texas 77030
Not listed San Antonio Texas 78212
Not listed Tyler Texas 75708
Not listed Salt Lake City Utah 84132
Not listed Colchester Vermont 05446
Not listed Charlottesville Virginia 22908
Not listed Norfolk Virginia 23507
Not listed Portsmouth Virginia 23708
Not listed Richmond Virginia 23298
Not listed Seattle Washington 98105
Not listed Seattle Washington 98195
Not listed Morgantown West Virginia 26506
Not listed Milwaukee Wisconsin 53201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01180634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 17, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01180634 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →